Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Streptamer-selected multiantigen-specific donor T-cell transfer after T-cell depleted allo-SCT
NL-OMON40919Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2014
- Countries
- 1
01
Overview
Phase 2, open-label trial in hematopoietic malignancies, leukemia, lymphoma and 3 more, sponsored by Leiden University Medical Center. Primary endpoint: Cumulative incidence of severe acute GVHD. Started Nov 2014; status: recruiting.
02
Conditions
hematopoietic malignanciesleukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON40919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40919.